Vancomycin hydrochloride - Kurobe

Drug Profile

Vancomycin hydrochloride - Kurobe

Latest Information Update: 09 Mar 2016

Price : $50

At a glance

  • Originator Kurobe LLC
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Conjunctivitis

Most Recent Events

  • 01 May 2015 Phase-III clinical trials in Conjunctivitis in USA (Ophthalmic) (NCT02432807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top